What is Geron Corp's earnings per share (EPS)?

Geron Corp (GERN) reported diluted earnings per share of $-0.13 for fiscal year 2025. This represents a 51.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Geron Corp Financials

GERN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Geron Corp (GERN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Geron Corp passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.33x

For every $1 of reported earnings, Geron Corp generates $1.33 in operating cash flow (-$111.0M OCF vs -$83.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-2.1x

Geron Corp earns $-2.1 in operating income for every $1 of interest expense (-$68.6M vs $32.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$68.1M

YoY+60.7%

Geron Corp's EBITDA was -$68.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 60.7% from the prior year.

Net Income

-$83.5M

YoY+52.2%

Geron Corp reported -$83.5M in net income in fiscal year 2025. This represents an increase of 52.2% from the prior year.

EPS (Diluted)

$-0.13

YoY+51.9%

Geron Corp earned $-0.13 per diluted share (EPS) in fiscal year 2025. This represents an increase of 51.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$77.6M

YoY-1.8%

5Y CAGR+50.9%

10Y CAGR+13.8%

Geron Corp held $77.6M in cash against $119.5M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

640M

YoY+5.5%

5Y CAGR+15.6%

10Y CAGR+15.0%

Geron Corp had 640M shares outstanding in fiscal year 2025. This represents an increase of 5.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-37.0%

YoY+25.3pp

5Y CAGR-1.1pp

10Y CAGR-37.0pp

Geron Corp's ROE was -37.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$71.4M

YoY-31.1%

5Y CAGR+6.8%

10Y CAGR+14.9%

Geron Corp invested $71.4M in research and development in fiscal year 2025. This represents a decrease of 31.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GERN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$237K-60.2%	$596K-57.2%	$1.4M+450.6%	$253K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$71.4M-31.1%	$103.7M-17.0%	$125.0M+30.9%	$95.5M+11.4%	$85.7M+66.5%	$51.5M
SG&A Expenses	$159.3M+9.3%	$145.7M+110.8%	$69.1M+58.5%	$43.6M+47.1%	$29.7M+15.5%	$25.7M
Operating Income	-$68.6M+60.5%	-$173.7M+10.4%	-$193.9M-40.0%	-$138.6M-21.5%	-$114.0M-48.2%	-$76.9M
Interest Expense	$32.7M+76.5%	$18.5M+122.6%	$8.3M+20.8%	$6.9M+84.0%	$3.7M+392.1%	$760K
Income Tax	$75K-83.3%	$449K+1940.9%	$22K	N/A	N/A	N/A
Net Income	-$83.5M+52.2%	-$174.6M+5.2%	-$184.1M-29.8%	-$141.9M-22.2%	-$116.1M-53.6%	-$75.6M
EPS (Diluted)	$-0.13+51.9%	$-0.27+15.6%	$-0.32+13.5%	$-0.37-5.7%	$-0.35-25.0%	$-0.28

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	$47.2M-3.7%	$49.0M+23.8%	$39.6M	N/A	$28.3M+3105.3%	$882K+190.1%	$304K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$21.1M-3.1%	$21.7M+44.2%	$15.1M	N/A	$20.2M-34.5%	$30.8M+4.8%	$29.4M
SG&A Expenses	N/A	$39.0M+1.1%	$38.6M-3.6%	$40.0M	N/A	$35.9M-9.0%	$39.4M+45.6%	$27.1M
Operating Income	N/A	-$13.9M-11.5%	-$12.5M+25.4%	-$16.7M	N/A	-$28.2M+59.3%	-$69.3M-23.5%	-$56.1M
Interest Expense	N/A	$8.6M+1.5%	$8.5M+3.9%	$8.2M	N/A	$3.0M-8.2%	$3.3M-3.3%	$3.4M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$18.4M-12.5%	-$16.4M+17.4%	-$19.8M	N/A	-$26.4M+60.8%	-$67.4M-21.7%	-$55.4M
EPS (Diluted)	N/A	$-0.03-50.0%	$-0.02+33.3%	$-0.03	N/A	$-0.04+60.0%	$-0.10-11.1%	$-0.09

GERN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$570.5M-3.9%	$593.8M+50.7%	$394.1M+106.8%	$190.6M-15.7%	$226.0M-16.5%	$270.7M
Current Assets	$520.3M+6.0%	$491.0M+43.8%	$341.3M+89.4%	$180.2M-3.7%	$187.2M-6.3%	$199.9M
Cash & Equivalents	$77.6M-1.8%	$79.0M+12.8%	$70.0M+23.2%	$56.8M+63.0%	$34.9M+251.3%	$9.9M
Inventory	$116.6M+201.3%	$38.7M	N/A	N/A	N/A	N/A
Accounts Receivable	$37.0M+2.9%	$35.9M	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$344.7M+10.0%	$313.5M+114.5%	$146.1M+32.1%	$110.6M+11.0%	$99.6M+66.6%	$59.8M
Current Liabilities	$111.5M+26.3%	$88.3M-18.3%	$108.1M+40.9%	$76.7M+68.5%	$45.5M+47.1%	$30.9M
Long-Term Debt	$119.5M+0.9%	$118.5M+238.0%	$35.1M+16.0%	$30.2M-39.4%	$49.8M+107.3%	$24.0M
Total Equity	$225.9M-19.4%	$280.3M+13.1%	$247.9M+209.9%	$80.0M-36.7%	$126.4M-40.1%	$210.9M
Retained Earnings	-$1.9B-4.7%	-$1.8B-10.9%	-$1.6B-13.0%	-$1.4B-11.2%	-$1.3B-10.0%	-$1.2B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$570.5M+0.6%	$567.4M+2.2%	$555.2M-1.3%	$562.5M-5.3%	$593.8M+33.4%	$444.9M-1.0%	$449.4M-6.8%	$482.1M
Current Assets	$520.3M-0.4%	$522.3M+3.3%	$505.6M+2.0%	$495.8M+1.0%	$491.0M+23.3%	$398.1M+6.6%	$373.3M-17.3%	$451.5M
Cash & Equivalents	$77.6M-0.7%	$78.1M+0.5%	$77.7M-7.2%	$83.7M+6.0%	$79.0M+30.9%	$60.3M-48.4%	$116.9M-38.4%	$189.8M
Inventory	$116.6M+22.2%	$95.4M+38.0%	$69.1M+23.0%	$56.2M+45.2%	$38.7M+90.9%	$20.3M+2520.5%	$774K	N/A
Accounts Receivable	$37.0M+4.6%	$35.4M-3.4%	$36.6M+17.5%	$31.2M-13.3%	$35.9M+28.3%	$28.0M+3104.5%	$874K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$344.7M+8.2%	$318.7M+7.8%	$295.7M+0.5%	$294.2M-6.1%	$313.5M+105.3%	$152.7M+7.0%	$142.7M+4.0%	$137.2M
Current Liabilities	$111.5M+27.2%	$87.7M+36.4%	$64.3M+2.0%	$63.0M-28.6%	$88.3M-36.0%	$137.9M+33.2%	$103.5M-15.9%	$123.2M
Long-Term Debt	$119.5M+0.2%	$119.3M+0.2%	$119.0M+0.2%	$118.7M+0.2%	$118.5M+865.2%	$12.3M-66.4%	$36.5M+225.5%	$11.2M
Total Equity	$225.9M-9.2%	$248.7M-4.2%	$259.5M-3.2%	$268.2M-4.3%	$280.3M-4.1%	$292.3M-4.7%	$306.7M-11.1%	$344.9M
Retained Earnings	-$1.9B-1.6%	-$1.8B-1.0%	-$1.8B-0.9%	-$1.8B-1.1%	-$1.8B-1.5%	-$1.7B-1.5%	-$1.7B-4.1%	-$1.7B

GERN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$111.0M+49.2%	-$218.6M-30.3%	-$167.7M-31.7%	-$127.4M-33.3%	-$95.6M-43.4%	-$66.7M
Capital Expenditures	N/A	$680K-18.1%	$830K+92.6%	$431K+108.2%	$207K-48.4%	$401K
Free Cash Flow	N/A	-$219.3M-30.1%	-$168.6M-31.9%	-$127.8M-33.5%	-$95.8M-42.8%	-$67.1M
Investing Cash Flow	$107.2M+201.2%	-$106.0M+41.2%	-$180.3M-390.5%	$62.1M-13.7%	$71.9M+168.3%	-$105.3M
Financing Cash Flow	$2.3M-99.3%	$334.4M-7.6%	$362.0M+314.9%	$87.3M+79.7%	$48.6M-71.2%	$168.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$22.1M-62.5%	-$13.6M+50.5%	-$27.4M+42.9%	-$48.0M-9.2%	-$43.9M+25.4%	-$58.9M-10.2%	-$53.5M+14.1%	-$62.3M
Capital Expenditures	N/A	N/A	N/A	N/A	-$141K	$0-100.0%	$206K-66.5%	$615K
Free Cash Flow	N/A	N/A	N/A	N/A	-$44.1M+25.2%	-$58.9M-9.8%	-$53.7M+14.6%	-$62.9M
Investing Cash Flow	$21.1M+58.4%	$13.3M-34.3%	$20.3M-61.3%	$52.4M+150.7%	-$103.5M-18584.3%	-$554K+98.5%	-$36.1M-205.7%	$34.2M
Financing Cash Flow	$378K-30.3%	$542K-50.3%	$1.1M+326.2%	$256K-99.8%	$166.2M+4544.0%	$3.6M-78.7%	$16.8M-88.6%	$147.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GERN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-81832.9%-58586.3pp	-23246.6%-15062.9pp	-8183.7%+22216.7pp	-30400.4%
Net Margin	N/A	N/A	-77690.7%-53881.8pp	-23808.9%-15473.5pp	-8335.4%+21552.7pp	-29888.1%
Return on Equity	-37.0%+25.3pp	-62.3%+12.0pp	-74.3%+103.1pp	-177.4%-85.5pp	-91.8%-56.0pp	-35.9%
Return on Assets	-14.6%+14.8pp	-29.4%+17.3pp	-46.7%+27.7pp	-74.5%-23.1pp	-51.4%-23.4pp	-27.9%
Current Ratio	4.66-0.9	5.56+2.4	3.16+0.8	2.35-1.8	4.11-2.3	6.46
Debt-to-Equity	0.53+0.1	0.42+0.3	0.14-0.2	0.38-0.0	0.39+0.3	0.11
FCF Margin	N/A	N/A	-71127.9%-49683.2pp	-21444.6%-14570.0pp	-6874.6%+19628.6pp	-26503.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-29.4%-4.0pp	-25.4%+16.8pp	-42.2%	N/A	-99.8%+7761.1pp	-7860.9%+10604.2pp	-18465.1%
Net Margin	N/A	-39.0%-5.6pp	-33.4%+16.7pp	-50.1%	N/A	-93.5%+7546.2pp	-7639.8%+10580.6pp	-18220.4%
Return on Equity	N/A	-7.4%-1.1pp	-6.3%+1.1pp	-7.4%	N/A	-9.0%+12.9pp	-22.0%-5.9pp	-16.1%
Return on Assets	N/A	-3.3%-0.3pp	-2.9%+0.6pp	-3.5%	N/A	-5.9%+9.0pp	-15.0%-3.5pp	-11.5%
Current Ratio	4.66-1.3	5.96-1.9	7.870.0	7.87+2.3	5.56+2.7	2.89-0.7	3.61-0.1	3.67
Debt-to-Equity	0.53+0.0	0.48+0.0	0.46+0.0	0.44+0.0	0.42+0.4	0.04-0.1	0.12+0.1	0.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	-208.5%+5878.1pp	-6086.6%+14593.6pp	-20680.3%

Similar Companies

Zenas BioPharma Inc. ZBIO

$1.3B

Immunome Inc IMNM

$2.5B

Anavex Life Scie AVXL

$277.1M

Uniqure QURE

$1.1B

Taysha Gene Therapies, Inc. TSHA

$1.3B

Frequently Asked Questions

Is Geron Corp profitable?

No, Geron Corp (GERN) reported a net income of -$83.5M in fiscal year 2025.

What is Geron Corp's EBITDA?

Geron Corp (GERN) had EBITDA of -$68.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Geron Corp have?

As of fiscal year 2025, Geron Corp (GERN) had $77.6M in cash and equivalents against $119.5M in long-term debt.

What is Geron Corp's return on equity (ROE)?

Geron Corp (GERN) has a return on equity of -37.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Geron Corp's operating cash flow?

Geron Corp (GERN) generated -$111.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Geron Corp's total assets?

Geron Corp (GERN) had $570.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Geron Corp spend on research and development?

Geron Corp (GERN) invested $71.4M in research and development during fiscal year 2025.

How many shares does Geron Corp have outstanding?

Geron Corp (GERN) had 640M shares outstanding as of fiscal year 2025.

What is Geron Corp's current ratio?

Geron Corp (GERN) had a current ratio of 4.66 as of fiscal year 2025, which is generally considered healthy.

What is Geron Corp's debt-to-equity ratio?

Geron Corp (GERN) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Geron Corp's return on assets (ROA)?

Geron Corp (GERN) had a return on assets of -14.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Geron Corp's cash runway?

Based on fiscal year 2025 data, Geron Corp (GERN) had $77.6M in cash against an annual operating cash burn of $111.0M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Geron Corp's Piotroski F-Score?

Geron Corp (GERN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Geron Corp's earnings high quality?

Geron Corp (GERN) has an earnings quality ratio of 1.33x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Geron Corp cover its interest payments?

Geron Corp (GERN) has an interest coverage ratio of -2.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.